GNRH1 and breast carcinoma: Adjuvant endocrine therapy (AET) with tamoxifen (TAM), gonadotropin-releasing hormone (GnRH) agonists and aromatase inhibitors (AIs) has been the mainstay of treatment in hormone receptor positive (HR + ) breast cancer [7], [8].